Biotest AG: Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins
Biotest AG / Key word(s): Alliance / Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins - The agreement relates to CEVEC's proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia patients
The agreement relates to CEVEC's proprietary CAP(R) cells used for the production of recombinant proteins. Under the license agreement, Biotest utilizes CEVEC's expression system for the development, production and commercialization of these proteins, for example to treat haemophilia patients. "The technology from CEVEC with its cell expression system is an ideal complement for the future production of Biotest's recombinant candidates in development" says Dr. Jörg Schüttrumpf, Senior Vice President Global Research Biotest. About CEVEC's Technology About CEVEC:
Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
2015-07-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
Language: | English | |
Company: | Biotest AG | |
Landsteinerstraße 5 | ||
63303 Dreieich | ||
Germany | ||
Phone: | 0 61 03 - 8 01-0 | |
Fax: | 0 61 03 - 8 01-150 | |
E-mail: | investor_relations@biotest.de | |
Internet: | http://www.biotest.de | |
ISIN: | DE0005227235, DE0005227201 | |
WKN: | 522723, 522720 | |
Indices: | SDAX | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart | |
End of News | DGAP News-Service |
373747 2015-07-01 |